J&J raises its outlook, but adjusted earnings still carry deal costs

Adjusted earnings still contain an investment decision

Johnson & Johnson’s October 13 results present a useful test of what investors mean by underlying earnings. Third-quarter diluted GAAP earnings were $0.09 per share, while adjusted earnings were $2.59. Sales rose 5.9% to $25.4 billion, but adjusted EPS declined 7.5% from the year-earlier quarter. The company nevertheless raised its full-year adjusted EPS midpoint to $11.10.

Those facts are compatible. A comparison with last year asks a different question from a revision to the latest forecast. More importantly, an adjusted number does not automatically remove every unusual-looking cost. For JNJ, the research task is to identify which items management excludes, which investments remain in the adjusted result, and which future benefits are still uncertain. Treating the label as a complete economic explanation loses that distinction.

Separate the litigation charge from the research transactions

The earnings announcement attributes the low GAAP EPS to a special charge for the proposed talc resolution and to the Firefly Bio acquisition and Sail Biomedicines collaboration. It explicitly says adjusted EPS also reflects those transactions. Investors should therefore avoid interpreting the difference between GAAP and adjusted EPS as the total cost of all three developments.

The CFO’s prepared remarks describe a $5.5 billion ovarian talc agreement announced in July, subject to express participation by at least 95% of the remaining claims. Management said participation was trending toward that threshold. That is a company update on a conditional process, not confirmation that every condition has been satisfied.

Our interpretation is that the litigation question and the investment question require separate records. For litigation, track the participation condition and subsequent formal disclosures. For the transactions, track the accounting treatment, spending and development milestones. Combining them under a single “one-time” heading can hide the different reasons each matters to shareholders.

The original acquisition disclosure explains the treatment

The July 29 Firefly announcement said J&J completed the purchase for $1 billion in cash. It specified asset-acquisition accounting and an approximately $1 billion in-process research and development charge in the third quarter. The company expected dilution to adjusted EPS of approximately $0.46 in 2026 and $0.08 in 2027. Those were transaction-specific expectations at announcement, rather than newly reported quarterly results.

This original disclosure is valuable because it states that the transaction affects the adjusted measure too. The acquired platform adds a development opportunity; it does not establish a commercial return merely because the purchase closed. Nor does an immediate expense establish that the investment will fail. The cost recognition and the eventual research outcome belong on different timelines.

A practical analysis can keep the investment in the company’s published earnings measure while separately testing its potential payoff. That is more transparent than quietly adding it back to a valuation denominator. If an analyst creates an additional measure excluding the transaction, it should be clearly named, reconciled and presented alongside the company’s figures. It should never be passed off as reported adjusted EPS.

Do not reuse a combined dilution estimate as a standalone figure

In the October prepared remarks, management put the combined Firefly and Sail impact on 2026 adjusted EPS at $0.64 and the expected combined 2027 dilution at $1.36 per share. These are combined estimates for two transactions. They should not be substituted for Firefly’s standalone figures or described as a forecast for the entire company’s 2027 earnings.

This matters when rolling a model forward. Removing a current charge does not automatically reveal next year’s earnings power if development spending continues or changes. Build the comparison using consistent scope, period and earnings definitions. A full-year combined estimate cannot be compared directly with a single transaction’s quarterly charge without additional information.

The useful output is an explicit set of assumptions: what remains in the earnings base, what is excluded in an analyst-created sensitivity, and what development evidence would justify the capital allocated. Avoid giving the sensitivity a more authoritative label than the disclosure supports.

What would make the raised outlook more persuasive

The higher full-year midpoint improves management’s current forecast, but it does not settle the longer-term return on these investments. A stronger thesis would require continuing commercial performance and development progress sufficient to support the spending. A weaker thesis would emerge if spending persisted while relevant programs failed to advance. These are research conditions, not clinical predictions.

Keep the conclusion precise: J&J raised its outlook while reporting a quarter in which litigation accounting and research transactions affected earnings differently. The next useful step is a consistent earnings bridge and a separate milestone record. Neither the low GAAP EPS nor the adjusted figure alone captures the entire investment decision.